Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030
Small Molecule Innovator API CDMO Market Growth & Trends
The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.53% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.
Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.
The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.
Small Molecule Innovator API CDMO Market Report Highlights
- The clinical stage type segment dominated the market with a share of 54.68% in 2023. Growth in the segment can be attributed to the rising clinical trial (phase I-III) activities for diverse formulations, growing small molecule development pipeline, increasing availability of specialized expertise, timesaving & cost-efficiency for investigational drugs, and innovations. Moreover, rising funding for drug development is propelling segment growth
- Based on the customer type, the pharmaceutical segment held the largest share in 2023 due to rapid advancements in pharmaceutical R&D for the development of advanced drugs. In addition, advancements in various therapies have shifted pharmaceutical companies' focus on CDMOs to developing novel small molecule innovator API drugs to treat numerous diseases
- The oncology therapeutic area segment dominated the market and accounted for a share of 42.25% in 2023. The segment growth is driven by the increasing prevalence of cancer globally. In addition, growing demand for innovative small molecule innovator APIs, advancements in targeted therapies, and demand for oncology drugs innovations are the factors driving the oncology segment
- Asia Pacific dominated the market with a share of 41.53% in 2023 due to increasing prevalence of chronic diseases, demand for small molecule APIs & CDMO services, and improving healthcare infrastructure
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Regional Scope
- 1.1.2. Estimates and Forecast Timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR’s Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
- 1.3.5. Details of Primary Research
- 1.4. Information or Data Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Validation
- 1.5.1. Region Wise Market: Base Estimates
- 1.5.2. Global Market: CAGR Calculation
- 1.6. Model Details
- 1.6.1. Commodity Flow Analysis (Model 1)
- 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
- 1.6.3. QFD Model Sizing & Forecasting (Model 3)
- 1.6.4. Bottom-Up Approach (Model 4)
- 1.7. Market Definitions
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. Objectives
- 1.10.1. Objective - 1
- 1.10.2. Objective - 2
- 1.10.3. Objective - 3
- 1.10.4. Objective - 4
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Ancillary Market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing Demand for Small Molecule Drugs
- 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
- 3.2.1.3. Surge in Number of Clinical Trials
- 3.2.2. Market restraint analysis
- 3.2.2.1. Compliance Issues While Outsourcing
- 3.2.2.2. Changing Scenarios in Developing Economies
- 3.3. Technology Landscape
- 3.3.1. Integration Of Ai In Small Molecule Innovator API CDMO Market
- 3.3.1.1. Current Dynamics and Future Trends
- 3.3.1.1.1. Drug Discovery and Design
- 3.3.1.1.2. AI-Assisted Drug API Synthesis
- 3.3.1.1.3. Process Optimization
- 3.3.1.1.4. Supply Chain Management
- 3.3.1.1.5. Clinical Trial Optimization
- 3.3.1.1.6. Regulatory Compliance
- 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
- 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
- 3.4.2. Total Number of Clinical Trials by Region (2021 - 2023)
- 3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
- 3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
- 3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
- 3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
- 3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
- 3.4.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
- 3.5. Small Molecule Innovator API CDMO Market: Analysis Tools
- 3.5.1. Porter’s Five Forces Analysis
- 3.5.2. PESTEL Analysis
- 3.6. Impact of COVID-19 on Small Molecule Innovator CDMO Market
- 3.7. COVID-19 Impact Analysis
- Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
- 4.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
- 4.3.1. Preclinical
- 4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.3.2. Clinical
- 4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.3.2.2. Phase I
- 4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.3.2.3. Phase II
- 4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.3.2.4. Phase III
- 4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.3.3. Commercial
- 4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
- 5.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
- 5.3.1. Pharmaceutical
- 5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.1.2. Small
- 5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.1.3. Medium
- 5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.1.4. Large
- 5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.2. Biotechnology
- 5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.2.2. Small
- 5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.2.3. Medium
- 5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.2.4. Large
- 5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.1.1. Cardiovascular Diseases
- 6.1.2. Oncology
- 6.1.3. Respiratory Disorders
- 6.1.4. Neurology
- 6.1.5. Metabolic Disorders
- 6.1.6. Infectious Diseases
- 6.1.7. Others
- 6.2. Therapeutic Area Market Share, 2023 & 2030
- 6.3. Segment Dashboard
- 6.4. Global Small Molecule Innovator API CDMO Market Movement Analysis
- 6.5. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
- 6.5.1. Cardiovascular Diseases
- 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.2. Oncology
- 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.3. Respiratory Disorders
- 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.4. Neurology
- 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.5. Metabolic Disorders
- 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.6. Infectious Diseases
- 6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.7. Others
- 6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
- Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application
- 7.1. Regional Market Dashboard
- 7.2. Global Regional Market Snapshot
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Scenario
- 7.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Scenario
- 7.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Scenario
- 7.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Scenario
- 7.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Scenario
- 7.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Scenario
- 7.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Scenario
- 7.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Scenario
- 7.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Scenario
- 7.5.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competitive Scenario
- 7.5.9.3. Regulatory Scenario
- 7.5.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Scenario
- 7.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.3. Japan
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Scenario
- 7.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Scenario
- 7.6.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Scenario
- 7.6.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Scenario
- 7.6.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Scenario
- 7.6.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.8. Taiwan
- 7.6.8.1. Key Country Dynamics
- 7.6.8.2. Competitive Scenario
- 7.6.8.3. Regulatory Scenario
- 7.6.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Scenario
- 7.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.3. Mexico
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Scenario
- 7.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.4. Argentina
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory Scenario
- 7.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Scenario
- 7.8.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Scenario
- 7.8.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Scenario
- 7.8.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory Scenario
- 7.8.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.6. Israel
- 7.8.6.1. Key Country Dynamics
- 7.8.6.2. Competitive Scenario
- 7.8.6.3. Regulatory Scenario
- 7.8.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Service Heat Map Analysis (a comparative analysis of the players together)
- 8.3. Company Profiles
- 8.4. Company Profiles
- 8.4.1. Strategy Mapping
- 8.4.2. Expansion
- 8.4.3. Partnerships
- 8.4.4. Acquisitions
- 8.5. Vendor Landscape
- 8.5.1. Key company market share analysis, 2023
- 8.5.2. Lonza Group Ltd.
- 8.5.2.1. Company overview
- 8.5.2.2. Financial performance
- 8.5.2.3. Product/service benchmarking
- 8.5.2.4. Strategic initiatives
- 8.5.3. Novo Holdings (Catalent, Inc.)
- 8.5.3.1. Company overview
- 8.5.3.2. Financial performance
- 8.5.3.3. Product/service benchmarking
- 8.5.3.4. Strategic initiatives
- 8.5.4. Thermo Fisher Scientific, Inc.
- 8.5.4.1. Company overview
- 8.5.4.2. Financial performance
- 8.5.4.3. Product/service benchmarking
- 8.5.4.4. Strategic initiatives
- 8.5.5. Siegfried Holding AG
- 8.5.5.1. Company overview
- 8.5.5.2. Financial performance
- 8.5.5.3. Product/service benchmarking
- 8.5.5.4. Strategic initiatives
- 8.5.6. Recipharm AB
- 8.5.6.1. Company overview
- 8.5.6.2. Financial performance
- 8.5.6.3. Product/service benchmarking
- 8.5.6.4. Strategic initiatives
- 8.5.7. CordenPharma International
- 8.5.7.1. Company overview
- 8.5.7.2. Financial performance
- 8.5.7.3. Product/service benchmarking
- 8.5.7.4. Strategic initiatives
- 8.5.8. Samsung Biologics
- 8.5.8.1. Company overview
- 8.5.8.2. Financial performance
- 8.5.8.3. Product/service benchmarking
- 8.5.8.4. Strategic initiatives
- 8.5.9. Labcorp
- 8.5.9.1. Company overview
- 8.5.9.2. Financial performance
- 8.5.9.3. Product/service benchmarking
- 8.5.9.4. Strategic initiatives
- 8.5.10. Ajinomoto Bio-Pharma Services
- 8.5.10.1. Company overview
- 8.5.10.2. Financial performance
- 8.5.10.3. Product/service benchmarking
- 8.5.10.4. Strategic initiatives
- 8.5.11. Piramal Pharma Solutions
- 8.5.11.1. Company overview
- 8.5.11.2. Financial performance
- 8.5.11.3. Product/service benchmarking
- 8.5.11.4. Strategic initiatives
- 8.5.12. Jubilant Life Sciences (Jubilant Biosys Limited)
- 8.5.12.1. Company overview
- 8.5.12.2. Financial performance
- 8.5.12.3. Product/service benchmarking
- 8.5.12.4. Strategic initiatives
- 8.5.13. WuXi AppTec Co., Ltd.
- 8.5.13.1. Company overview
- 8.5.13.2. Financial performance
- 8.5.13.3. Product/service benchmarking
- 8.5.13.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook